| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | PD318088 | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | BMS-509744 | GDSC1000 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.9 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |